Iterum Therapeutics Announces Partnership for Commercialization Services U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (th...
Dorchester Minerals, L.P. Announces Retirement and Appointment to the Board of Managers DALLAS, May 19, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP). As previously announced, Ron Trout retired as an Independent Manager of the Partnership after the conclusion of his term, which ended immediately following the 2025 Annual Meeting. Casey McManemin, Chairman of the Board, stated “I would like to thank Ron for 17 years of dedicated service to the Board of Managers. His business acumen and insights have made a meaningful contribution to the Board.” In ...
Iterum Therapeutics Announces Extension of Term of Promissory Note DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029. “We are very pleased to announce that Pfizer has agreed to extend th...
Iterum Therapeutics Reports First Quarter 2025 Financial Results --Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. “Based on pre-commercial...
Dorchester Minerals, L.P. Announces First Quarter Results DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended March 31, 2025 of $17,642,000, or $0.36 per common unit. A comparison of the Partnership’s consolidated results for the quarter ended March 31, 2025 and 2024 are set forth below: Three Months Ended March 31, 2025 2024Operating Revenues $43,164,000 $30,979,000Net Income $17,642,000 $18,167,000Net Income Per Common Unit $0.36 $0.44 The Partnership previ...
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to ...
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today closed the previously announced purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded ...
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at ...
Dorchester Minerals, L.P. Announces Its First Quarter Distribution DALLAS, April 24, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s first quarter 2025 cash distribution. The distribution of $0.725835 per common unit represents activity for the three-month period ended March 31, 2025 and is payable on May 15, 2025 to common unitholders of record as of May 5, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the first quarter totaled approximately $34.2 million. Approximately 68% of these receipts reflect oi...
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 1...
Dorchester Minerals, L.P. Announces 2024 Results DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the year ended December 31, 2024 of $92,449,000 or $2.13 per common unit. A comparison of the Partnership’s consolidated results for the twelve month periods ended December 31, 2024 and 2023 are set forth below: Twelve Months Ended December 31, 2024 2023 Operating Revenues$161,523,000 $163,799,000 Net Income$92,449,000 $114,117,000 Net Income Per Common Unit$2.13 $2.85 The Partnersh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.